A detailed history of Engineers Gate Manager LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Engineers Gate Manager LP holds 20,920 shares of CRSP stock, worth $1.11 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
20,920
Previous 4,968 321.1%
Holding current value
$1.11 Million
Previous $310,000 359.68%
% of portfolio
0.04%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $967,807 - $1.42 Million
15,952 Added 321.1%
20,920 $1.43 Million
Q4 2023

Feb 14, 2024

SELL
$38.62 - $72.18 $16,452 - $30,748
-426 Reduced 7.9%
4,968 $310,000
Q3 2023

Nov 14, 2023

BUY
$45.39 - $59.0 $244,833 - $318,246
5,394 New
5,394 $244,000
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $389,352 - $652,431
9,935 New
9,935 $403,000
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $58,274 - $99,522
-1,348 Reduced 7.15%
17,513 $1.06 Million
Q1 2022

May 16, 2022

BUY
$53.19 - $79.24 $476,103 - $709,277
8,951 Added 90.32%
18,861 $1.18 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $482,499 - $766,120
6,884 Added 227.5%
9,910 $751,000
Q3 2021

Nov 15, 2021

SELL
$110.2 - $156.64 $193,290 - $274,746
-1,754 Reduced 36.69%
3,026 $339,000
Q2 2021

Aug 16, 2021

BUY
$100.84 - $161.89 $482,015 - $773,834
4,780 New
4,780 $774,000
Q2 2020

Aug 17, 2020

SELL
$38.5 - $76.05 $789,635 - $1.56 Million
-20,510 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$33.68 - $62.53 $324,035 - $601,601
9,621 Added 88.36%
20,510 $870,000
Q4 2019

Feb 14, 2020

SELL
$36.68 - $73.13 $4,108 - $8,190
-112 Reduced 1.02%
10,889 $663,000
Q3 2019

Nov 14, 2019

BUY
$40.99 - $52.56 $450,930 - $578,212
11,001 New
11,001 $451,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.14B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.